CTSOHealthcare · Medical DevicesThe 1 Wall Street analysts covering CytoSorbents Corp. hold a median 12-month price target of $2.38 — +534.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 47 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores CytoSorbents Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (21): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CTSO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +534.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | $10 |
| 12 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 May 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 1 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTSO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 80% of US stocks
Cheaper than 99% of US stocks
Cheaper than 77% of US stocks
Higher than 28% of US stocks
Higher than 35% of US stocks
Higher than 85% of US stocks
Higher than 20% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CytoSorbents Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cytosorbents Corporation held its Q2 2026 earnings call, and the full transcript of the call was published by Seeking Alpha.
Why it matters — The transcript provides CTSO watchers with the company's own commentary on its second-quarter 2026 performance and outlook directly from management.
CytoSorbents reported its financial results for the second quarter ended June 30, 2026, along with recent business highlights and a regulatory update. The announcement was made on August 6, 2026, and highlights four independent drivers of shareholder value.
Why it matters — A CTSO watcher would care because the report provides an update on the company's financial performance, business progress, and regulatory status of its blood purification products for intensive care and cardiac surgery.
The 1 Wall Street analysts covering CytoSorbents Corp. have a median 12-month price target of $2.38, with estimates ranging from $0.75 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering CytoSorbents Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoSorbents Corp. 47 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, CytoSorbents Corp. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +534.3% from the last close, and Ticker Nerd's factor model ranks CytoSorbents Corp. 47 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CytoSorbents Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTSO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $4 over the next 12 months.
CytoSorbents Corp. returned -55.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Cytosorbents Corporation is a biotechnology company that specializes in advanced blood purification technologies designed to treat life-threatening conditions in intensive care units and other hospital settings. The company's flagship product, CytoSorb, is a hemoadsorption cartridge that removes cytokines and other inflammatory mediators from blood.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "Cytosorbents Corporation (CTSO) Q2 2026 Earnings Call Transcript". Cytosorbents Corporation held its Q2 2026 earnings call, and the full transcript of the call was published by Seeking Alpha.
Cytosorbents Corporation is a biotechnology company that specializes in advanced blood purification technologies designed to treat life-threatening conditions in intensive care units and other hospital settings. The company's flagship product, CytoSorb, is a hemoadsorption cartridge that removes cytokines and other inflammatory mediators from blood. This device aims to help control excessive inflammation, which is a critical factor in numerous conditions such as sepsis, cardiac surgery, and trauma. Cytosorbents operates predominantly within the healthcare and medical technology sectors, with its technologies gaining attention for their potential impact on critical care and immunotherapy. Given its focus on innovative medical solutions, the company plays a pivotal role in advancing treatment protocols and improving patient outcomes. Headquartered in Princeton, New Jersey, Cytosorbents continues to expand its reach globally, participating in various clinical trials and partnerships to enhance the adoption and efficacy of its products in modern medical practice.
CEO Dr. Phillip P. Chan M.D., Ph.D. · 129 employees · United States · https://www.cytosorbents.com